Search Results - "Angiolillo, D"

Antiplatelet therapy: new pharmacological agents and changing paradigms by Capodanno, D., Ferreiro, J. L., Angiolillo, D. J.

“…Summary Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or those undergoing percutaneous coronary intervention (PCI) are…”
Get full text

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies by Angiolillo, D J, Gibson, C M, Cheng, S, Ollier, C, Nicolas, O, Bergougnan, L, Perrin, L, LaCreta, F P, Hurbin, F, Dubar, M

“…Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between…”
Get full text

Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation by Capra, V., Bäck, M., Angiolillo, D. J., Cattaneo, M., Sakariassen, K. S.

“…Summary The activation of thromboxane prostanoid (TP) receptor on platelets, monocytes/macrophages, endothelial cells, and vascular smooth muscle cells (SMC)…”
Get full text

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability by Angiolillo, Dominick J., Fernández-Ortiz, Antonio, Bernardo, Esther, Ramírez, Celia, Sabaté, Manel, Bañuelos, Camino, Hernández-Antolín, Rosana, Escaned, Javier, Moreno, Raul, Alfonso, Fernando, Macaya, Carlos

“…Aim To assess platelet inhibitory effects, interindividual variability in platelet inhibition as well as response to a 600 mg, compared to a standard 300 mg,…”
Get full text

New perspectives in antiplatelet therapy by Tello-Montoliu, A, Jover, E, Rivera, J, Valdés, M, Angiolillo, D J, Marín, F

“…Platelet activation is a complex mechanism of response to vascular injury and atherothrombotic disease, leading to thrombus formation. A wide variety of…”
Get more information

Platelet thrombin receptor antagonism and atherothrombosis by Angiolillo, Dominick J., Capodanno, Davide, Goto, Shinya

“…Clinical manifestations of atherothrombotic disease, such as acute coronary syndromes, cerebrovascular events, and peripheral arterial disease, are major…”
Get full text

Findings of intravascular ultrasound during acute stent thrombosis by Alfonso, F, Suárez, A, Angiolillo, D J, Sabaté, M, Escaned, J, Moreno, R, Hernández, R, Bañuelos, C, Macaya, C

“…Objective: To evaluate the potential role of intravascular ultrasound (IVUS) in evaluating patients experiencing an episode of acute stent thrombosis. Design…”
Get full text

Safety and efficacy of protease‐activated receptor‐1 antagonists in patients with coronary artery disease: a meta‐analysis of randomized clinical trials by CAPODANNO, D., BHATT, D. L., GOTO, S., O’DONOGHUE, M. L., MOLITERNO, D. J., TAMBURINO, C., ANGIOLILLO, D. J.

“…Background:  Thrombin receptor antagonists blocking protease‐activated receptor‐1 (PAR‐1) on platelets represent a new class of oral antiplatelet agents for…”
Get full text

Current concepts on coronary revascularization in diabetic patients by Roffi, Marco, Angiolillo, Dominick J., Kappetein, A. Pieter

“…Diabetic mellitus (DM) patients with coronary artery disease (CAD) are at higher risk of cardiovascular events compared with non-DM individuals. While…”
Get full text

Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification by Price, M. J., Baker, B. A., Jakubowski, J. A., Li, W., Heiselman, D. E., Angiolillo, D. J.

“…Summary Background On‐treatment platelet reactivity (OTR) is a predictor of clinical outcomes in patients receiving thienopyridine therapy. Objective To assess…”
Get full text

Tackling the diabetic platelet: is high clopidogrel dosing the answer? by ANGIOLILLO, D. J.

Get full text

Platelet monitoring for PCI: which test is the one to choose? by Capodanno, D, Angiolillo, D J

“…Despite the clinical benefit associated with the combined use of aspirin and clopidogrel in patients with acute coronary syndrome or those undergoing…”
Get more information

Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial by Jiménez-Quevedo, Pilar, Sabaté, Manel, Angiolillo, Dominick J., Alfonso, Fernando, Hernández-Antolín, Rosana, SanMartín, Marcelo, Gómez-Hospital, Joan Antoni, Bañuelos, Camino, Escaned, Javier, Moreno, Raúl, Fernández, Cristina, Fernández-Avilés, Francisco, Macaya, Carlos

“…Aims Sirolimus stent implantation has been demonstrated to be safe and effective in diabetics; however, the long-term outcomes in this high-risk population…”
Get full text

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome by Galli, M, Gargiulo, G, Benenati, S, Mehran, R, Angiolillo, D J

“…Abstract Background The use of bivalirudin in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) has been…”
Get full text

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes by Schüpke, Stefanie, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Bernlochner, Isabell, Wöhrle, Jochen, Richardt, Gert, Liebetrau, Christoph, Witzenbichler, Bernhard, Antoniucci, David, Akin, Ibrahim, Bott-Flügel, Lorenz, Fischer, Marcus, Landmesser, Ulf, Katus, Hugo A, Sibbing, Dirk, Seyfarth, Melchior, Janisch, Marion, Boncompagni, Duino, Hilz, Raphaela, Rottbauer, Wolfgang, Okrojek, Rainer, Möllmann, Helge, Hochholzer, Willibald, Migliorini, Angela, Cassese, Salvatore, Mollo, Pasquale, Xhepa, Erion, Kufner, Sebastian, Strehle, Axel, Leggewie, Stefan, Allali, Abdelhakim, Ndrepepa, Gjin, Schühlen, Helmut, Angiolillo, Dominick J, Hamm, Christian W, Hapfelmeier, Alexander, Tölg, Ralph, Trenk, Dietmar, Schunkert, Heribert, Laugwitz, Karl-Ludwig, Kastrati, Adnan

“…A randomized trial involving patients with acute coronary syndromes showed that prasugrel was superior to ticagrelor with regard to the incidence of death,…”
Get full text

Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina by LIUZZO, Giovanna, ANGIOLILLO, Dominick J, BUFFON, Antonino, RIZZELLO, Vittoria, COLIZZI, Christian, GINNETTI, Francesca, BIASUCCI, Luigi M, MASERI, Attilio

“…C-reactive protein (CRP) plasma levels have been associated with short- and long-term occurrence of coronary events. We investigated whether circulating…”
Get full text

Ticagrelor with or without Aspirin in High-Risk Patients after PCI by Mehran, Roxana, Baber, Usman, Sharma, Samin K, Cohen, David J, Angiolillo, Dominick J, Briguori, Carlo, Cha, Jin Y, Collier, Timothy, Dangas, George, Dudek, Dariusz, Džavík, Vladimír, Escaned, Javier, Gil, Robert, Gurbel, Paul, Hamm, Christian W, Henry, Timothy, Huber, Kurt, Kastrati, Adnan, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell, Kunadian, Vijay, Marx, Steven O, Mehta, Shamir R, Moliterno, David, Ohman, E. Magnus, Oldroyd, Keith, Sardella, Gennaro, Sartori, Samantha, Shlofmitz, Richard, Steg, P. Gabriel, Weisz, Giora, Witzenbichler, Bernhard, Han, Ya-ling, Pocock, Stuart, Gibson, C. Michael

“…In this placebo-controlled trial, 7119 patients were randomly assigned at 3 months after PCI to either receive ticagrelor alone or continue dual therapy with…”
Get full text

Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes by BIASUCCI, Luigi M, LIUZZO, Giovanna, CIERVO, Alessandra, PETRUCCA, Andrea, PIRO, Maddalena, ANGIOLILLO, Dominick J, CREA, Filippo, CASSONE, Antonio, MASERI, Attilio

“…Heat shock proteins (HSPs) are a family of proteins with immunogenic and proinflammatory properties. Human and Chlamydia pneumoniae (Cp) HSP60 were found in…”
Get full text

Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease by Galli, M, Capodanno, D, D'Amario, D, Andreotti, F, Crea, F, Angiolillo, D J

“…Abstract Background The use of low dose of direct oral anticoagulants (DOAC) in adjunct to antiplatelet therapy, known as dual pathway inhibition (DPI), has…”
Get full text

P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis by Galli, M, Laudani, C, Occhipinti, G, Spagnolo, M, Gragnano, F, D'amario, D, Navarese, E P, Mehran, R, Valgimigli, M, Capodanno, D, Angiolillo, D J

“…Abstract Background P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) has been proposed as an alternative to standard…”
Get full text